Related Experiment Videos

The reporting of harms in randomized controlled trials of hypertension using the CONSORT criteria for harm reporting

Nitin Babulal Bagul1, Jamie J Kirkham

  • 1Clinical Development, Novartis Horsham Research Centre, Horsham, UK. drnitinbb@yahoo.co.uk

Clinical and Experimental Hypertension (New York, N.Y. : 1993)
|May 11, 2012
PubMed

Insights

Reporting of harms in hypertension clinical trials is inadequate. Most trials fail to meet the Consolidated Standards of Reporting Trials (CONSORT) harms reporting standards, compromising evidence reliability.

Area of Science:

  • Clinical Trials Methodology
  • Cardiovascular Research
  • Patient Safety

Background:

  • Accurate reporting of harms is crucial for evaluating treatment safety.
  • Hypertension clinical trials are a key source of cardiovascular evidence.
  • Existing reporting guidelines, like the CONSORT extension for harms, aim to improve data quality.

Purpose of the Study:

  • To evaluate the quality of harms reporting in hypertension clinical trials.
  • To assess adherence to the CONSORT extension for harms reporting.
  • To identify gaps in the reporting of adverse events in hypertension research.

Main Methods:

  • Systematic review of hypertension clinical trials from the Cochrane Database.
  • Application of the CONSORT extension for harms reporting checklist.
  • Quantitative assessment of reported harms items.

Main Results:

  • Forty-one hypertension trials were analyzed.
  • On average, trials reported less than half of the recommended harms reporting items (mean 9.83 items).
  • Significant deficiencies were observed in the measurement, analysis, and reporting of harms data.

Conclusions:

  • Current reporting of harms in hypertension trials is suboptimal.
  • Improvements are needed in how trialists measure, analyze, and report adverse events.
  • Enhanced harms reporting is essential for reliable and balanced clinical trial evidence.

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Errors occurring during blood pressure monitoring01:25

Errors occurring during blood pressure monitoring

Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the patient.